EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

salicyl amide
benzamide, 2-hydroxy-

Supplier Sponsors

Name:2-hydroxybenzamide
CAS Number: 65-45-2Picture of molecule3D/inchi
ECHA EINECS - REACH Pre-Reg:200-609-3
FDA UNII: EM8BM710ZC
Nikkaji Web:J1.408G
Beilstein Number:0742439
MDL:MFCD00007978
XlogP3:1.30 (est)
Molecular Weight:137.13819000
Formula:C7 H7 N O2
BioActivity Summary:listing
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:cosmetic agents
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 FDA/DG SANTE Petitions, Reviews, Notices:
FCN 46 Salicylamide View - notice
 
Physical Properties:
Appearance:white or slightly pink crystals (est)
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Melting Point: 142.00 °C. @ 760.00 mm Hg
Boiling Point: 181.50 °C. @ 760.00 mm Hg
Flash Point: 295.00 °F. TCC ( 146.30 °C. ) (est)
logP (o/w): 1.280
Soluble in:
 water, 2060 mg/L @ 25 °C (exp)
 water, 2.64e+004 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
CosIng:cosmetic data
Cosmetic Uses: keratolytics
 
Suppliers:
Allan Chemical
Salicylamide
BOC Sciences
For experimental / research use only.
Hydrochlorothiazide Related Compound > 95%
Odor: characteristic
Use: Hydrochlorothiazide Related Compound is a non-prescription drug with analgesic and antipyretic properties. It is used in combination with both aspirin and caffeine in the over-the-counter pain remedy PainAid.
George Uhe Company
Salicylamide
Penta International
SALICYLAMIDE USP
Sigma-Aldrich: Aldrich
For experimental / research use only.
Salicylamide 99%
TCI AMERICA
For experimental / research use only.
Salicylamide >98.0%(T)
 
Safety Information:
Preferred SDS: View
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
intraperitoneal-cat LDLo 1000 mg/kg
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951.

oral-cat LDLo 150 mg/kg
Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 572, 1955.

intraperitoneal-dog LDLo 1000 mg/kg
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951.

oral-guinea pig LD50 1730 mg/kg
BEHAVIORAL: TREMOR BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 47, Pg. 479, 1958.

intraperitoneal-guinea pig LDLo 1000 mg/kg
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951.

intraperitoneal-mouse LD50 180 mg/kg
Bollettino Chimico Farmaceutico. Vol. 111, Pg. 293, 1972.

intravenous-mouse LD50 313 mg/kg
BEHAVIORAL: GENERAL ANESTHETIC
Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951.

oral-mouse LD50 300 mg/kg
Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 572, 1955.

oral-rabbit LD50 3200 mg/kg
Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 572, 1955.

intraperitoneal-rabbit LDLo 1000 mg/kg
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Journal of Pharmacology and Experimental Therapeutics. Vol. 101, Pg. 119, 1951.

intraperitoneal-rat LD50 600 mg/kg
Journal of Pharmacology and Experimental Therapeutics. Vol. 108, Pg. 450, 1953.

oral-rat LD50 980 mg/kg
LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 47, Pg. 479, 1958.

Dermal Toxicity:
subcutaneous-mouse LD50 300 mg/kg
Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 25, 1958.

Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
cosmetic agents
Recommendation for salicyl amide usage levels up to:
 not for fragrance use.
 
Recommendation for salicyl amide flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
Chemical Carcinogenesis Research Information System:Search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA Substance Registry Services (TSCA):65-45-2
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :5147
National Institute of Allergy and Infectious Diseases:Data
WGK Germany:2
2-hydroxybenzamide
Chemidplus:0000065452
EPA/NOAA CAMEO:hazardous materials
RTECS:VN6475000 for cas# 65-45-2
 
References:
 2-hydroxybenzamide
NIST Chemistry WebBook:Search Inchi
Canada Domestic Sub. List:65-45-2
Pubchem (cid):5147
Pubchem (sid):134972625
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):D01811
HMDB (The Human Metabolome Database):Search
Export Tariff Code:2924.21.4500
ChemSpider:View
Wikipedia:View
Formulations/Preparations:
•salicylamide, nf capsules, 200 mg, with methapyrilene hydrochloride 50 mg & scopolamine aminoxide hydrobromide 500 ug (sominex); capsules, 324 mg, with methapyrilene hydrochloride 12 mg & scopolamine aminoxide hydrobromide 150 mg (devarex). •tablets, nf, 230 mg (amid-sal) & 600 mg (salrin); tablets, 200 mg with methapyrilene hydrochloride 25 mg (nytol); with scopolamine aminoxide hydrobromide 250 ug (sominex); tablets, 250 mg with methapyrilene hydrochloride 25 mg & scopolamine hydrobromide 200 ug (sure-sleep). •liquiprin...oral: soln 60 mgml; salamide...salicim...oral: tablets 300 mg; salrin...oral: tablets 300 & 600 mg. •grades: technical; nf.
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
 acket
 afko-sal
 algamon
 algiamida
 algiamide
 allevin
 amid-sal
 amidosal
 anamid
 andasol
 benesal
 benzamide, 2-hydroxy-
 benzamide, o-hydroxy-
 benzoic acid, 2-hydroxy-, amide
2-carbamoylphenol
2-carboxamidophenol
 cdial
 cetamide
 cymidon
 dolomide
 dropsprin
 eggosalil
 flarpirina
2-hydroxy-benzamide
2-hydroxybenzamide
o-hydroxybenzamide
ortho-hydroxybenzamide
2-hydroxybenzoicacidamide
 liquiprin
 morsarinas
 novecyl
 oramid
 panithal
 raspberin
 rasperin
 salamide
 saliamid
 saliamin
 salicim
 salicylamide
 salicylic acid amide
 salipur
 salizell
 salrin
 salymid
 samid
 serramida
 urtosal
 

Articles:

PubMed:Effects of Sho-saiko-to extract and its components, Baicalin, baicalein, glycyrrhizin and glycyrrhetic acid, on pharmacokinetic behavior of salicylamide in carbon tetrachloride intoxicated rats.
PubMed:In vitro efficacy of nitro- and bromo-thiazolyl-salicylamide compounds (thiazolides) against Besnoitia besnoiti infection in Vero cells.
PubMed:Identification of metoclopramide metabolites in the urine of cattle by gas chromatography-mass spectrometry and high-performance liquid chromatography-photodiode array detection.
PubMed:Glucuronidation of morphine and six beta 2-sympathomimetics in isolated rat intestinal epithelial cells.
PubMed:Induction of tachyzoite egress from cells infected with the protozoan Neospora caninum by nitro- and bromo-thiazolides, a class of broad-spectrum anti-parasitic drugs.
PubMed:Inhibitory effects of lipophilic acids and related compounds on bacteria and mammalian cells.
 
Notes:
None found
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy